1. Home
  2. LION vs MIRM Comparison

LION vs MIRM Comparison

Compare LION & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LION
  • MIRM
  • Stock Information
  • Founded
  • LION 1997
  • MIRM 2018
  • Country
  • LION United States
  • MIRM United States
  • Employees
  • LION N/A
  • MIRM N/A
  • Industry
  • LION Movies/Entertainment
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • LION Consumer Discretionary
  • MIRM Health Care
  • Exchange
  • LION Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • LION 1.9B
  • MIRM 3.3B
  • IPO Year
  • LION N/A
  • MIRM 2019
  • Fundamental
  • Price
  • LION $7.17
  • MIRM $73.79
  • Analyst Decision
  • LION Buy
  • MIRM Strong Buy
  • Analyst Count
  • LION 9
  • MIRM 10
  • Target Price
  • LION $8.88
  • MIRM $74.20
  • AVG Volume (30 Days)
  • LION 2.6M
  • MIRM 699.8K
  • Earning Date
  • LION 11-06-2025
  • MIRM 11-11-2025
  • Dividend Yield
  • LION N/A
  • MIRM N/A
  • EPS Growth
  • LION N/A
  • MIRM N/A
  • EPS
  • LION N/A
  • MIRM N/A
  • Revenue
  • LION $3,986,900,000.00
  • MIRM $429,161,000.00
  • Revenue This Year
  • LION N/A
  • MIRM $53.08
  • Revenue Next Year
  • LION $16.90
  • MIRM $20.45
  • P/E Ratio
  • LION N/A
  • MIRM N/A
  • Revenue Growth
  • LION 10.89
  • MIRM 62.33
  • 52 Week Low
  • LION $5.55
  • MIRM $36.86
  • 52 Week High
  • LION $8.50
  • MIRM $78.10
  • Technical
  • Relative Strength Index (RSI)
  • LION 60.90
  • MIRM 61.09
  • Support Level
  • LION $6.10
  • MIRM $73.35
  • Resistance Level
  • LION $7.69
  • MIRM $76.87
  • Average True Range (ATR)
  • LION 0.32
  • MIRM 2.38
  • MACD
  • LION 0.10
  • MIRM -0.82
  • Stochastic Oscillator
  • LION 66.98
  • MIRM 30.84

About LION Lionsgate Studios Corp. Common Shares

Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: